Form 4: Artiva CEO Fred Aslan Sells 25,500 Shares

Artiva Biotherapeutics' President and CEO, Fred Aslan, reported the sale of 25,500 shares of common stock at $6 per share, executed under a Rule 10b5-1 plan.

Summary

• Fred Aslan, President and CEO of Artiva Biotherapeutics, Inc. (ARTV), reported a transaction involving the sale of common stock.
• The transaction occurred on October 17, 2025, and involved the disposition of 25,500 shares of common stock.
• The shares were sold at a price of $6 per share.
• This sale was executed pursuant to a Rule 10b5-1 Plan, which was adopted by Fred Aslan on July 23, 2024.
• Following this transaction, Fred Aslan directly beneficially owns 356,721 shares of Artiva Biotherapeutics common stock.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even under a pre-arranged 10b5-1 plan, can sometimes be interpreted cautiously by the market. However, the pre-planned nature mitigates immediate negative sentiment.

Negatives

• President and CEO Fred Aslan sold 25,500 shares of common stock, which can sometimes be viewed cautiously by the market.

Related Party Transactions

• Fred Aslan, President and CEO, sold 25,500 shares of Artiva Biotherapeutics common stock.

Stakeholder Impact

• Shareholders may view the insider sale with caution, though the pre-arranged 10b5-1 plan suggests a planned divestment rather than a reactive one.

Key Dates

Recommendation

The reported transaction is an insider sale by the CEO, Fred Aslan, executed under a Rule 10b5-1 plan. While insider selling can sometimes be a negative signal, the pre-arranged nature of the 10b5-1 plan suggests a planned divestment rather than a reactive one based on new, undisclosed information. Without additional context on the company's financial performance or strategic outlook, this single transaction does not provide sufficient grounds for a strong buy or sell recommendation. A 'hold' recommendation is appropriate as investors should monitor future filings and company performance for more comprehensive insights.

Keywords

Artiva Biotherapeutics, ARTV, Fred Aslan, Insider Sale, Form 4, Stock Transaction, CEO, Biotechnology, Rule 10b5-1 Plan